Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Shares IssuedShares Outstanding
Ratios

Krystal Biotech (KRYS) Accumulated Depreciation & Amortization (2021 - 2025)

Historic Accumulated Depreciation & Amortization for Krystal Biotech (KRYS) over the last 5 years, with Q3 2025 value amounting to $29.2 million.

  • Krystal Biotech's Accumulated Depreciation & Amortization rose 4740.03% to $29.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $29.2 million, marking a year-over-year increase of 4740.03%. This contributed to the annual value of $21.9 million for FY2024, which is 7088.17% up from last year.
  • As of Q3 2025, Krystal Biotech's Accumulated Depreciation & Amortization stood at $29.2 million, which was up 4740.03% from $26.7 million recorded in Q2 2025.
  • In the past 5 years, Krystal Biotech's Accumulated Depreciation & Amortization registered a high of $29.2 million during Q3 2025, and its lowest value of $2.8 million during Q4 2021.
  • Over the past 5 years, Krystal Biotech's median Accumulated Depreciation & Amortization value was $9.1 million (recorded in 2023), while the average stood at $12.0 million.
  • As far as peak fluctuations go, Krystal Biotech's Accumulated Depreciation & Amortization skyrocketed by 4644.28% in 2022, and later skyrocketed by 21632.55% in 2023.
  • Krystal Biotech's Accumulated Depreciation & Amortization (Quarter) stood at $2.8 million in 2021, then surged by 46.44% to $4.1 million in 2022, then surged by 216.33% to $12.8 million in 2023, then surged by 70.88% to $21.9 million in 2024, then soared by 33.09% to $29.2 million in 2025.
  • Its Accumulated Depreciation & Amortization was $29.2 million in Q3 2025, compared to $26.7 million in Q2 2025 and $24.3 million in Q1 2025.